Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;121(5):1822-6.
doi: 10.1172/JCI46110. Epub 2011 Apr 11.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

Barbara Savoldo  1 , Carlos Almeida Ramos, Enli Liu, Martha P Mims, Michael J Keating, George Carrum, Rammurti T Kamble, Catherine M Bollard, Adrian P Gee, Zhuyong Mei, Hao Liu, Bambi Grilley, Cliona M Rooney, Helen E Heslop, Malcolm K Brenner, Gianpietro Dotti
Affiliations

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

Barbara Savoldo et al. J Clin Invest. 2011 May.

Abstract

Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR+ T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Transduction efficiency and phenotypic/function profile of T cell lines.
(A) FACS and Q-PCR analyses showing transduction efficiency with CAR.CD19ζ and CAR.CD19-28ζ vectors (left). Bars indicate mean values for peripheral blood samples from 6 patients (Supplemental Table 1). Each symbol represents an individual cell line. Representative histograms of T cells transduced with CAR.CD19ζ and CAR.CD19-28ζ vectors from patients number 1 and number 5 are also presented (right). Numbers represent the percentage of CAR+ cells. (B) Results of a 4-hour 51Cr-release assay at an effector/tumor cell (E/T) ratio of 20:1. Target cells were Raji (CD19+, CD80+, CD86–), a Burkitt lymphoma cell line; HLDM-2 (CD19–, CD80+, CD86+), a Hodgkin lymphoma cell line; and K562 (CD19–, CD80–, CD86–), an erythroid leukemia cell line that is susceptible to natural killer cell activity. Both CAR.CD19ζ+ and CAR.CD19-28ζ+ T cells specifically targeted CD19+ tumors. Data are mean ± SD for the 6 T cell lines. (C) Phenotypic composition of CAR.CD19ζ+ or CAR.CD19-28ζ+ T cells. These products contained both CD8+ and CD4+ CAR-expressing T cells that are predominantly CD45RO+CD62L+, with a fraction of them expressing CD28. Each symbol represents an individual cell line, and horizontal bars denote mean group values.
Figure 2
Figure 2. In vivo expansion and persistence of infused CAR.CD19ζ+ versus CAR.CD19-28ζ+ T cell lines as assessed by Q-PCR in peripheral blood.
Data points represent critical postinfusion intervals after the first or second infusion of modified T cells. Patients number 1, number 3, and number 5, who had stable disease or clinical benefit at 6 weeks after the first T cell infusion, received a second infusion of CAR-modified T lymphocytes. Patient number 1 received only CAR.CD19-28ζ+ T cells (2 × 107 cells/m2, the same as for the first infusion), because this was the only product available. Patient number 3 received both CAR.CD19-28ζ+ and CAR.CD19ζ+ T cells, but the cell dose was 60% of their first dose (1 × 108 cells/m2). Patient number 5 received both CAR.CD19-28ζ+ and CAR.CD19ζ+ T cells at the same dose administered during their first infusion (2 × 108 cells/m2). Open arrows indicate the time of T cell infusion, and dashed arrows indicate the time when chemotherapy was initiated for disease progression. Pre, before the first infusion; Pre II, before the second infusion.
Figure 3
Figure 3. Detection of CAR+ T cells in a skin tumor biopsy.
(A) Immunohistochemical examination (diaminobenzidine with hematoxylin counterstaining) of a punch biopsy of a lymphoma skin lesion from patient number 5 at 2 weeks after T cell infusion showed that tumor cells were CD20+ (shown), CD10+, BCL2+, and BCL6+, consistent with involvement by follicular lymphoma with large cell transformation. Scattered CD3+ CD8+ cells infiltrated the tumor. Of note, the infused CAR.CD19-28ζ+ product consisted of 85% CD8+ cells. Scale bar: 100 μm. (B) FACS analysis of a cell suspension obtained from a fragment of the tumor biopsy. Viable cells represented approximately 45% of the preparation. The far left panel shows the gate on CD45+ cells, which represented 12% of the viable cells. The middle panel shows the CD3+ lymphocytes infiltrating the tumor, which accounted for 6.7% of CD45+ cells (0.8% of all viable cells). The far right panel illustrates that 20% of the gated CD3+ lymphocytes cells coexpressed the CAR, as assessed by the Fc-Cy5 monoclonal antibody, which binds to the IgG1-CH2CH3 spacer region of the CD19-specific CARs (~0.16% of all viable cells). SSC, side scatter.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. doi: 10.1038/nrc2355. - DOI - PMC - PubMed
    1. Bollard CM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838–2845. doi: 10.1182/blood-2007-05-091280. - DOI - PMC - PubMed
    1. Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–1270. doi: 10.1038/nm.1882. - DOI - PMC - PubMed
    1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724. doi: 10.1073/pnas.90.2.720. - DOI - PMC - PubMed
    1. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215–223. doi: 10.1016/j.coi.2009.02.009. - DOI - PMC - PubMed

Publication types